Opinion statement
In-transit metastases for melanoma are a type of stage III regional metastatic disease that are intradermal or subcutaneous nodules growing within lymphatics and not in nodal basins. If the initial diagnosis is a limited number of in-transit metastases (1-3 nodules), the optimal management is simple surgical excision with minimal negative margins and primary closures and appropriate staging to look for any distant metastases. There is no role for wide excision of in-transit lesions as there is for primary melanoma because the entire extremity or that region of the body is at risk for recurrence. Patients who are diagnosed with additional lesions in a short period of time or patients who at initial diagnosis have large numbers of nodules are candidates for isolated limb perfusion (ILP). ILP is a regional administration of high-dose chemotherapeutics within an extremity using a cardiopulmonary bypass machine similar to cardiac surgery. Once isolation is obtained surgically, the limb is heated to what is considered mild hyperthermia (38.5°-40° C), then chemotherapeutics are administered at very high concentrations for a 60-to 90-minute treatment. The drug recirculates and, at the end of the treatment period, it is flushed from the extremity and the circulation is re-established. The optimal regimen is melphalan dosed per limb volume (10 mg/L limb volume for lower extremities and 13 mg/L limb volume for upper extremities) with mild hyperthermia for 60 minutes. Using this regimen, overall response rates between 80% and 90% and complete response rates between 55% and 65% can be obtained. The duration of response is typically 9 to 12 months and a subgroup of complete responders, which is 20% to 25% of the total patient population, typically have sustained complete responses. The major toxicities are skin erythema, myopathy, and peripheral neuropathy. There have been several studies adding highdose tumor necrosis factor to ILP, but there is no clear benefit in the treatment of melanoma. Other new approaches include isolated limb infusion as a percutaneous procedure to avoid the surgical toxicity.
Similar content being viewed by others
References and Recommended Reading
Creech O Jr, Krementz ET, Ryan RF, Winblad JN: Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958, 148:616–632.
Krementz ET, Carter RD, Sutherland CM, et al.: Regional chemotherapy for melanoma: a 35-year experience. Ann Surg 1994, 220:520–534.
Fraker DL: Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg 1999, 36:841–908. This is a comprehensive review of ILP for melanoma and sarcoma.
Balch C, Buzaid AC, Soong SJ, et al.: Prognostic factors analysis of 17,600 melanoma patients: validation of the AJCC melanoma staging system. J Clin Oncol 2001, 19:3622–3634.
Koops HS, Vaglini M, Suciu S, et al.: Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998, 16:2906–2912. This article is the largest prospective randomized trial for adjuvant ILP for high-risk resected primary melanoma. It shows improvement in local recurrences, but it shows no change in survival.
Hafstrom L, Rudenstam CM, Blomquist E, et al.: Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991, 9:2091–2094. This is the smallest but best prospective randomized trial for adjuvant ILP for resected in-transit metastatic melanoma. There is a significant improvement in disease-free survival and a trend toward improving overall survival.
Jaques DP, Coit DG, Brennan MF: Major amputation for advanced malignant melanoma. Surg Gynecol Obstet 1989, 169:1–6.
Stehlin JS, Giovanella BC, de Ipolyi PD, et al.: Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 1975, 140:339–348.
Daryanani D, Komdeur R, Ter Veen J, et al.: Continuous leakage measurement during hyperthermic isolated limb perfusion. Ann Surg Oncol 2001, 8:564–565.
Roberts MS, Wu ZY, Siebert GA, et al.: Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res 2001, 11:423–431.
Wieberdink J, Benckhuysen C, Braat RP, et al.: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982, 18:905–910.
Norda A, Loos U, Sastry M, et al.: Pharmacokinetics of melphalan in isolated limb perfusion. Cancer Chemother Pharmacol 1999, 43:35–42.
Lejeune FJ, Ghanem GE: A simple and accurate new method for cytostatic dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination. Cancer Res 1987, 47:639–643.
Thompson JF, Gianoutsos MP: Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992, 16:227–233. This article is one of the best summaries of other antineoplastic agents other than melphalan used for ILP. It reports detailed results seen with cisplatin, actinomycin-D, and dacarbazine.
Hoekstra HJ, Koops HS, de Vries LGE, et al.: Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer 1993, 72:1224–1229.
Lienard D, Lejeune F, Delmotte J, et al.: High doses of rTNFa in combination with IFN-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992, 10:52–60.
Lienard D, Lejeune F, Ewalenko I: In transit metastases of malignant melanoma treated by high doses of rTNFa in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 1992, 16:234–240. This article reported the first phase II study combining high-dose TNF and IFN-g with a standard melphalan ILP. It reported a 90% complete response rate with this combination.
Ghussen F, Kruger I, Groth W, et al.: The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 1988, 61:654–659.
Klaase JM, Kroon BB, van Geel AN, et al.: Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994, 115:39–45. This article represents multi-institutional combined data for therapeutic limb perfusions using melphalan alone with mild hyperthermia or normothermia. It is the best data reflecting the response rates that can be achieved in current practice with melphalan alone.
Klaase JM, Kroon BB, van Geel AN, et al.: Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 1994, 178:564–572.
Fraker DL, Alexander HR, Pass HI: Biologic therapy of tumor necrosis factor: clinical applications by systemic and regional administration. In Biologic Therapy of Cancer. Edited by DeVita V, Hellman S, Rosenberg SA. Philadelphia: JB Lippincott; 1995:329.
Lejeune FJ: High dose recombinant tumour necrosis factor (rTNFa) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur J Cancer 1995, 31A:1009–1016.
Posner MC, Lienard D, Lejeune FJ, et al.: Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am 1995, 1:274.
Lienard D, Eggermont AM, Koops HS, et al.: Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999, 9:491–502. This article is a prospective randomized study comparing melphalan and TNF with or without IFN-g in ILP for melanoma. It indicates that there is no significant difference by adding low-dose IFN-g.
Fraker DL, Alexander HR, Bartlett DL, et al.: A prospective randomized trial of therapeutic isolated limb perfusion (ILP) comparing melphalan (M) versus melphalan, tumor necrosis factor (TNF) and interferon-g (IFN): an initial report [abstract]. Soc Surg Oncol 1996, 49:6.
Fraker, DL, Alexander HR, Ross M, et al.: A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon-gamma (IFN). Ann Surg Oncol 2002, 9:S8.
Fraker DL, Alexander HR, Andrich M, et al.: Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon-gamma: results of a TNF dose escalation study. J Clin Oncol 1996, 14:479–489. This is a phase I/II trial with dose escalation of the TNF. This paper shows that the maximally tolerated dose of TNF in ILP is 4 mg with the limitation being regional toxicity.
Ma G, Alexander HR, Bartlett DL, et al.: Isolated limb perfusion (ILRe) with tumor necrosis factor (TNF) and melphalan (M) for extremity melanoma after failure of isolated limb perfusion (ILP) with chemotherapeutics [abstract]. Soc Surg Oncol 1996, 49:53.
Vaglini M, Belli F, Ammatuna M, et al.: Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gammainterferon, and melphalan. Cancer 1994, 73:483–492.
Olieman AF, Koops HS, Geertzen JH, et al.: Functional morbidity of hyperthermic isolated regional perfusion of the extremities. Ann Surg Oncol 1994, 3:382–388.
Vrouenraets BC, in’t Veld GJ, Nieweg OE, et al.: Longterm functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur J Surg Oncol 1999, 25:503–508.
Bonifati DM, Ori C, Rossi CR, et al.: Neuromuscular damage after hyperthermic isolated limb perfusion in patients with melanoma or sarcoma treated with chemotherapeutic agents. Cancer Chemother Pharmacol 2000, 46:517–522.
Vrouenraets BC, Hart GA, Eggermont AM, et al.: Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. JAMA 1999, 188:522–530.
Thom AK, Alexander HR, Andrich MP, et al.: Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon-gamma and melphalan. J Clin Oncol 1913:264–273.
Stam TC, Swaak AJ, de Vries MR, et al.: Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol 2000, 7:268–275.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fraker, D.L. Management of in-transit melanoma of the extremity with isolated limb perfusion. Curr. Treat. Options in Oncol. 5, 173–184 (2004). https://doi.org/10.1007/s11864-004-0009-3
Issue Date:
DOI: https://doi.org/10.1007/s11864-004-0009-3